IDH1 and neoplasm: It has been shown that 80% of IDH mutations were enriched in C5 (16), and in fact, IDH mutations can decrease tumor-associated immune cells and improve prognosis by reducing leukocyte chemotaxis (28, 29), while the high-risk group was mainly concentrated in the C4 phenotype and contained a higher level of immune antigenicity, immunomodulation, and leukocyte infiltration, which was associated with a poorer prognosis.